Committee Recommends Sanofi’s Multaq For Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite issues with ATHENA and ANDROMEDA, committee recommends approval of Multaq, but not with the mortality claim Sanofi-Aventis hoped for.